Showing results (311-320 of 324) with videos related to

Sort By:
Pageof 33
Hippocampus|July 30, 2025
Developing an Anatomically Valid Segmentation Protocol for Anterior Regions of the Medial Temporal Lobe for Neurodegenerative DiseasesNiyousha Sadeghpour, Sydney A Lim, Anika Wuestefeld, et al.
Gut|September 22, 2020
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patientsOlga P Nyssen, Dmitry Bordin, Bojan Tepes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2021
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)Olga P Nyssen, Dino Vaira, Ángeles Pérez Aísa, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
Brain : a Journal of Neurology|July 14, 2021
Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobePaul A Yushkevich, Mónica Muñoz López, María Mercedes Iñiguez de Onzoño Martin, et al.
Antibiotics (Basel, Switzerland)|December 30, 2020
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in SpainMaría Caldas, Ángeles Pérez-Aisa, Manuel Castro-Fernández, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Pageof 33